NCT06596616View on ClinicalTrials.gov

Gadopiclenol vs Gadoxetate MRI for Liver Lesions

Enrolling by invitationOBSERVATIONAL
Enrollment

75

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

March 27, 2026

Study Completion Date

March 27, 2026

Conditions
Liver Lesion
Interventions
OTHER

Radiology

Radiology - MRI Scans

OTHER

Gadopiclenol

Gadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)

Trial Locations (1)

10029

BMEII, New York

Sponsors

Collaborators (1)

Guerbet
All Listed Sponsors
collaborator

Guerbet

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT06596616 - Gadopiclenol vs Gadoxetate MRI for Liver Lesions | Biotech Hunter | Biotech Hunter